BioInvent International
23.11.2021 17:38:03 CET | ACCESS Newswire | Press release
LUND, SE / ACCESSWIRE / November 23, 2021 / BioInvent International (STO:BINV)
Friday, December 17 at 1 pm ET (7 pm CET)
BI-1206 is a Potential Treatment for non-Hodgkin's Lymphoma and Solid Tumors
BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a key opinion leader (KOL) webinar on BI-1206, a potential treatment for non-Hodgkin's lymphoma and solid tumors, on Friday, December 17, 2021 at 1:00pmET/7:00pmCET.
The webcast will feature KOL Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current treatment landscape and unmet medical need in treating patients with non-Hodgkin's lymphoma (NHL) and Mantle Cell Lymphoma (MCL).
BioInvent's management team will provide an update on the ongoing BI-1206 clinical studies for the treatment of non-Hodgkin's lymphoma and solid tumors, including an overview of the NHL data presented at ASH on December 11.
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
BI-1206 is a monoclonal antibody that selectivity binds to FcγRIIB (CD32B). By blocking FcγRIIB, BI-1206 can recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of NHL. In addition, BI-1206 has the potential to reduce resistance to PD-1 immune checkpoint blockade, providing a new way to enhance anti-tumor immune responses in patients with solid tumors.
To register for the event, please click here.
Luhua (Michael) Wang, M.D. is a Professor in the department of Lymphoma & Myeloma at MD Anderson. Dr. Wang obtained his M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. He completed his clinical training as a resident at Norwalk Hospital, Norwalk, Connecticut, and as a Fellow in Oncology and in Hematology at MD Anderson.
Dr. Wang has published more than 150 peer-reviewed papers and presented his work at meetings nationally and internationally. He is the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.
During the past 15 years, he has focused on preclinical and clinical research and established an MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. Dr. Wang has pioneered the work to improve the treatment of patients with MCL, including the introduction of BTK inhibitors such as ibrutinib and acalabrutinib in the treatment algorithm, and has performed extensive work with CAR-T cells for the treatment of these patients. His work has been published in the most prestigious medical journals such as the NEJM and the Lancet. He is currently the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.
About BioInvent
BioInvent International AB (Nasdaq Stockholm:BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
Attachments
BioInvent Hosting Key Opinion Leader Webinar on BI-1206
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/674388/BioInvent-Hosting-Key-Opinion-Leader-Webinar-on-BI-1206
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OMP and PwC Alliance Moves Process Manufacturers from Siloed Supply Chain Planning to Unified Decisions23.9.2026 14:25:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / September 23, 2026 / OMP and PwC have formed an alliance to bring unified, faster supply chain decisions to process manufacturers in life sciences, consumer goods, and chemicals. Planning in these industries runs on campaign production, long lead times, and regulatory requirements, all surfacing "too late to act on" when planning sits in separate systems. The alliance combines Unison Planning™, OMP's AI-enabled planning platform with built-in industry expertise, and PwC's implementation services. German specialty pharmaceutical company medac is already live under the alliance, with its planners working on a single demand plan in Unison Planning™. PwC and medac will present the project on October 15, 2026, at the OMP Conference in Singapore, detailing the approach behind the rollout and what it means for planning in pharma. Combining innovation, industry knowledge, and integration OMP and PwC run each implementation as a single program. OMP brings Uniso
SmartVendor Brings Autonomous Retail to the Czech Parliament; Clears Europe's Toughest Privacy Bar with SHEKEL WeightAI(TM)23.9.2026 11:20:00 CEST | Press release
PRAGUE, CZ / ACCESS Newswire / September 23, 2026 / SmartVendor today announced the deployment of an autonomous, AI-powered retail solution inside the Chamber of Deputies of the Parliament of the Czech Republic, built on the WeightAI™ platform from SHEKEL Scales Ltd., the weight-based AI technology and solution provider behind the next generation of autonomous retail. For public institutions across Europe, autonomous retail has presented a compliance contradiction: the technology that makes unattended stores work typically relies on cameras, and cameras mean GDPR risk. The Czech Parliament resolved that contradiction by choosing a solution built on WeightAI™. No cameras. No biometrics. No personal data captured at the point of purchase. Full GDPR compliance by design. The installation, deployed by SmartVendor on the Innovendi Elite platform, marks one of the first deployments of an autonomous AI-powered retail solution inside a major state institution in the Czech Republic. Members of
Fermi and TensorWave Agree to Extend Closing Date to October 31, 202622.9.2026 22:01:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / September 22, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced that its wholly owned subsidiary, Fermi Campus 1 LLC, and TensorWave TEX1, LLC ("TensorWave") have signed a First Amendment to their Data Center Lease and Services Agreement (the "Lease"). The amendment extends the closing date under the Lease from September 30, 2026 to October 31, 2026. All other terms of the Lease remain unchanged and in effect. The Lease covers 222 megawatts (MW) of total facility power at Fermi's Project Matador campus and represents approximately $6.5 billion in expected total revenue over its initial 15-year term. Parties Working Constructively Toward Closing The Lease, signed in August 2026, provides that its effectiveness is subject to the satisfaction or waiver of specified closing conditions. Those conditions include executing and delivering related work letters and guaranties; finalizing operations sc
Leggett Dynamics Expands Asia Pacific Headquarters22.9.2026 17:00:00 CEST | Press release
SHANGHAI, CHINA / ACCESS Newswire / September 22, 2026 / Leggett Dynamics today celebrated the grand opening of its expanded Asia Pacific headquarters in Shanghai, China marking the latest investment in the company's growth strategy for the region. The expanded facility includes 40 percent more office space, an innovation showroom and multifunctional space for training, events and enhanced collaboration among customers, suppliers and internal teams. "We're not simply expanding our Asia Pacific headquarters in Shanghai. We're expanding our capability to innovate faster, collaborate more closely and create greater value for our customers. This is critical in a hyper competitive market like China which is redefining the user experience in vehicles and turning comfort and motion into the new battleground globally for brand differentiation," said Marinela Cirstea, President of Leggett Dynamics. Today's grand opening in Shanghai reflects Leggett Dynamics' long-term commitment to Asia Pacific
MicroVision Introduces Advanced Photonics Technology for Next-Generation AI Data Center Scale-Up Architecture22.9.2026 15:20:00 CEST | Press release
REDMOND, WA / ACCESS Newswire / September 22, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, security and defense, and automotive applications today announced the introduction by its wholly owned Scantinel subsidiary of an advanced photonics solution designed to address power efficiency and performance challenges critical for next-generation AI data center scale-up architectures and other intelligent infrastructure applications. As the global photonics community gathers in Málaga, Spain this week for the 52nd European Conference on Optical Communication and the Global Photonics Economic Forum, Scantinel revealed its new external laser small form-factor pluggable (ELSFP) module that provides a centralized, serviceable light source for co-packaged optics (CPO) systems in existing and next-generation AI data centers and photonics-enabled AI and cloud infrastructure. Scantinel's differentiated ELSFP technology is built around its core phot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom